Escitalopram
| Escitalopram | |
|---|---|
| Salts [] | |
|---|---|
| Escitalopram oxalate | |
| Escitalopram hydrobromide | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 324.40 g/mol [1] |
| Melting point | 147-152C [1] |
| Solubility | Sparingly soluble [1] |
| Predicted LogP | 3.2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C20H21FN2O |
| IUPAC name | (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile |
| SMILES | CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F |
| InChI | InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1 |
| InChIKey | WSEQXVZVJXJVFP-FQEVSTJZSA-N |
| CAS number | 128196-01-0 |
| UNII | 4O4S742ANY |
| PubChem CID | 146570 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | ~27–32 hours |
| Metabolism | Liver (CYP2C19, CYP3A4, CYP2D6) |
| Excretion | Urine (major; 8–10% unchanged), feces (minor) |
| Routes of administration | By mouth |
Escitalopram (also known as (S)-Citalopram, S(+)-Citalopram, Cipralex, Seroplex, S-(+)-Citalopram, Esertia, (+)-Citalopram, Esitol, escitalopramum or (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile) is a substance of the alkylbenzene class.
Chemistry
Salts []
Stereochemistry []
Escitalopram is a single defined stereoisomer (optical activity ( + )).
Druglikeness
Lipinski's rule of five
Escitalopram matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- antidepressants (N06A)
- selective serotonin reuptake inhibitors (N06AB)
- (N06AB10)
- escitalopram (N06AB10)
MeSH Classification
- selective serotonin reuptake inhibitors (M0556972)
Mechanism of action []
Escitalopram, like other selective serotonin re-uptake inhibitors, enhances serotonergic activity by binding to the orthosteric (i.e. primary) binding site on the serotonin transporter (SERT), the same site to which endogenous 5-HT binds, and thus prevents the re-uptake of serotonin into the presynaptic neuron. Escitalopram, along with [paroxetine], is also considered an allosteric serotonin re-uptake inhibitor - it binds to a secondary allosteric site on the SERT molecule to more strongly inhibit 5-HT re-uptake. Its combination of orthosteric and allosteric activity on SERT allows for greater extracellular 5-HT levels, a faster onset of action, and greater efficacy as compared to other SSRIs. The sustained elevation of synaptic 5-HT eventually causes desensitization of 5-HT<sub>1A</sub> auto-receptors, which normally shut down endogenous 5-HT release in the presence of excess 5-HT - this desensitization may be necessary for the full clinical effect of SSRIs and may be responsible for their typically prolonged onset of action. Escitalopram has shown little-to-no binding affinity at a number of other receptors, such as histamine and muscarinic receptors, and minor activity at these off-targets may explain some of its adverse effects. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP2D6 | metabolism / inhibition / induction | 365 (15 contraindicated) |
|---|---|---|
| CYP3A4 | metabolism / induction / inhibition | 259 (4 contraindicated) |
| CYP2C19 | metabolism / inhibition / induction | 95 (2 contraindicated) |
| SLC6A4 | shared target | 60 |
| AOX1 | metabolism | 3 |
Subjective effects []
Experience reports
Legal status []
- Australia: Escitalopram is a Schedule 4.[3]
- Brazil: Escitalopram is a C1.[4]
- Canada: Escitalopram is Prescription only.
- United Kingdom: Escitalopram is Prescription only.
- United States: Escitalopram is Prescription only.[5]
- European Union: Escitalopram is Prescription only.[6]
- Other: Escitalopram is a Rx-only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 146570, Escitalopram. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/146570
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Escitalopram. UNII: 4O4S742ANY. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/4O4S742ANY
Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration. 21 June 2022. https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Lexapro- escitalopram tablet, film coated; Lexapro- escitalopram solution. DailyMed. 17 November 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13bb8267-1cab-43e5-acae-55a4d957630a
Active substance(s): escitalopram. List of nationally authorised medicinal products. September 2022. https://www.ema.europa.eu/documents/psusa/escitalopram-list-nationally-authorised-medicinal-products-psusa/00001265/202112_en.pdf
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 09:34:31 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 09:34:27 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 09:34:27 |
| gsrs | ok | 2026-11-20 09:34:29 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0005028) | 2026-11-20 09:34:27 |
| kegg | ok | 2026-11-20 09:34:31 |
| pubchem | ok | 2026-11-20 09:34:27 |
| ok | 2026-11-20 09:34:27 | |
| sider | missing (not in SIDER) | 2026-11-20 09:34:27 |
| structure | ok | 2026-11-20 09:34:27 |
| wikipedia | ok | 2026-11-20 09:34:28 |